COMPANY PROFILE

Holobiome

Explore full profile

Innovative therapies from the human microbiome to address nervous system disorders and major health challenges

Boston, United StatesFounded 2015Biotech & Life Sciences

Valuation $50–100M Last recorded · 2024

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Holobiome

Holobiome is a pioneering biotech company focused on developing groundbreaking therapies derived from the human microbiome. Founded by research scientists from Northeastern University, the company aims to unlock the potential of gut microbes to improve global health. Holobiome operates in the healthcare and biotechnology market, primarily serving patients with nervous system disorders and other significant health issues. The company's business model revolves around rigorous scientific research and development, translating emerging microbiome science into practical medical solutions. Revenue is generated through the development and commercialization of these innovative therapies. Holobiome is driven by a commitment to patient care and scientific excellence, positioning itself as a leader in microbiome-based treatments.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2015
Headquarters: Boston, United States
Employees: 19
Open positions: None listed
Dealroom signal: 83.4/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
Technology: Artificial Intelligence
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn X

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

8 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SEED✓Equity / VC	Oct 2024	$9M	$36M	Valor Equity Partners · Azeem Azhar · Astanor Ventures · SkyRiver Ventures	↗
EARLY VC✓Equity / VC	Mar 2024	$100K	$400K	One Mind	↗

Showing the latest 2 of 8 recorded eventsBook a demo for the full funding history →

Growth signals

Holobiome website traffic

Latest recorded traffic for Holobiome is 2.9K monthly website visits, up 123.1% over the last three months. Holobiome's team grew 18.8% over the past year.

Latest monthly visits2.9K 3-month web change+123.1% 1-year team growth+18.8%

Monthly website visitsOct 2020–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
HTHotHouse TherapeuticsAI-driven plant bioengineering for therapeutic molecule discovery	Norwich, United Kingdom	Operational	13	$3.8M	$15M
STScripta TherapeuticsAI-driven drug discovery modulating transcription factor activity	Oxford, United Kingdom	Operational
RBRidge BiotechnologiesAI-enabled platform for precision enzyme and drug design	Palo Alto, United States	Operational
SBSortera BioHarnessing Deep Screening to address the toughest challenges in biologics discovery	Cambridge, United Kingdom	Operational
DADaltontxAdaptive AI platform for pharmaceutical drug discovery	London, United Kingdom	Operational
DDDomus DiagnosticsAffordable, accurate, and easy-to-use diagnostic tests for everyone, everywhere	Park City, United States	Operational
ARArontierInnovative AI-driven solutions targeting cancer treatment through precision medicine and anti-CAF drug development	Seoul, South Korea	Operational
VIVilyaDeveloping a novel class of drugs that precisely target the biology of disease	Seattle, United States	Operational